Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma (vol 26, pg 487, 2013)

摘要

This article has been retracted at the request of Editors-in-Chief Andre Duranceau and John Pandolfino.Retraction: The following article from Diseases of the Esophagus, Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma' by X. F. Guo, X. F. Zhu, G. S. Zhong, and B. G. Deng, published online on 27 March 2012 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editors-in-Chief, Andre Duranceau and John Pandolfino, and Wiley Periodicals, Inc. The retraction has been agreed due to overlap with previously published material in: Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.' Oncol Rep 2012; 27: 1639-1645. Reference Guo, X. F., Zhu, X. F., Zhong, G. S. and Deng, B. G. (2012), Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.' Diseases of the Esophagus. doi: